Melanoma m (zero): diagnosis and therapy.

Area of Science:

• Dermatology
• Oncology
• Surgical Oncology

Background:

• Cutaneous melanoma is a significant public health concern.
• Early detection and accurate staging are crucial for effective treatment and improved patient outcomes.
• Understanding risk factors and prognostic indicators aids in personalized treatment strategies.

Purpose of the Study:

• To provide a comprehensive review of the epidemiology, diagnosis, and treatment of cutaneous melanoma.
• To highlight recent advancements in melanoma management.
• To identify key prognostic factors influencing survival and metastasis.

Main Methods:

• Literature review of epidemiological data, diagnostic methods, and treatment modalities for cutaneous melanoma.
• Analysis of prognostic factors including Breslow thickness, mitotic rate, ulceration, and growth phase.
• Evaluation of surgical interventions, adjuvant therapies, and palliative treatments.

Main Results:

• Breslow tumor thickness, mitotic rate, ulceration, and growth phase are critical predictors of survival and metastasis.
• Wide excision is the primary curative treatment for primary melanoma.
• Sentinel lymph node biopsy is indicated for melanomas >1 mm thick or thinner melanomas with adverse features (ulceration, high mitotic index).
• Isolated limb perfusion/infusion shows significant remission rates for in-transit metastases.
• Interferon alpha-2 is the only adjuvant treatment shown to impact survival.
• Adjuvant radiotherapy improves local control in high-risk patients post-lymph node dissection.

Conclusions:

• Accurate staging and risk stratification are essential for optimal melanoma management.
• Multimodal treatment approaches, including surgery, adjuvant therapies, and palliative care, are vital.
• Continued research into novel therapeutic agents and treatment strategies is warranted to improve melanoma patient outcomes.